Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.5.0.2
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Revenue:        
Contract research revenue $ 0 $ 59,858 $ 0 $ 194,494
Costs and Expenses:        
Research and development 835,308 879,196 2,399,595 3,682,336
General and administrative 999,803 1,339,430 3,293,233 3,641,337
Total costs and expenses 1,835,111 2,218,626 5,692,828 7,323,673
Loss from operations (1,835,111) (2,158,768) (5,692,828) (7,129,179)
Other income/(expense), net (3,325) 4,143 (14,103) (88)
Net loss (1,838,436) (2,154,625) (5,706,931) (7,129,267)
Convertible preferred stock beneficial conversion feature accreted as a deemed dividend (4,393,809) 0 (4,393,809) 0
Net loss attributable to common shareholders $ (6,232,245) $ (2,154,625) $ (10,100,740) $ (7,129,267)
Net loss available for common shareholders per share - basic and diluted $ (0.11) $ (0.04) $ (0.18) $ (0.14)
Weighted average common shares outstanding:        
Basic and diluted 57,628,917 56,970,295 57,505,788 49,574,729